A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants With 50% or Greater Scalp Hair Loss
Latest Information Update: 08 May 2025
At a glance
- Drugs IMG-007 (Primary)
- Indications Alopecia areata
- Focus Adverse reactions
- Sponsors Inmagene
Most Recent Events
- 30 Apr 2025 Status changed from active, no longer recruiting to completed.
- 24 Apr 2025 Results presented in the Inmagene Media Release.
- 30 Aug 2024 Planned End Date changed from 1 Oct 2024 to 1 Jan 2025.